Bellicum Pharmaceuticals NASDAQ: BLCM
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
Name | Bellicum Pharmaceuticals |
Ticker | BLCM |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price
52W Low/High |
3.41
2.71 / 9.03 |
Momentum | Sharp Down |
Market cap | 17 M |
1Y Total Return |
-48.10%
Weak |
1Y Volatility |
107.52%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
Details
Ticker | BLCM |
Name | Bellicum Pharmaceuticals |
ISIN | US0794811077 |
CUSIP | |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/13/21
Close Price | 3.41 |
52W Low/High | 2.71 / 9.03 |
Market cap | 17 M |
1Y Total Return |
-48.10%
Weak |
1Y Volatility |
107.52%
High Risk |
Beta | 1.97 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -1,544.4% |
Cash from Op. / Cur. Liabilities | -2.29 |
Diluted Earnings / Share | -1.34 |
ROE | - |
ROIC | - |
Price / Revenue | 39.3 |
Price / Book | -7.9 |
Price / CF | -0.3 |
Current Ratio | 1.6 |
Cur.Liabilities / Tot.Liabilities | 1.0 |
Financial Leverage | - |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
1
|
7
|
1
|
0
|
0
|
0
|
|
Gross Profit |
1
|
7
|
1
|
0
|
0
|
0
|
|
R&D |
39
|
65
|
72
|
66
|
51
|
34
|
|
EBITDA |
-3
|
-100
|
-87
|
-85
|
-65
|
-47
|
|
Operating Income |
-55
|
-87
|
-95
|
-87
|
-68
|
-49
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
6
|
5
|
4
|
3
|
3
|
3
|
|
EPS exc. Extra |
-1.34
|
-24.01
|
-24.37
|
-28.90
|
-25.70
|
-18.40
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
41
|
116
|
122
|
136
|
132
|
160
|
|
Cash, Eq & Invt ShortTerm |
37
|
94
|
93
|
105
|
113
|
94
|
|
Total Current Assets |
39
|
112
|
95
|
102
|
106
|
97
|
|
Total Non-Current Assets |
1
|
4
|
26
|
34
|
26
|
64
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
25
|
121
|
53
|
51
|
35
|
8
|
|
Total Current Liabilities |
25
|
94
|
16
|
12
|
15
|
7
|
|
Long Term Debt |
0
|
27
|
37
|
39
|
20
|
1
|
|
Shareholder equity |
-2
|
-26
|
68
|
85
|
97
|
152
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-57
|
-78
|
-75
|
-73
|
-50
|
-36
|
|
Depreciation |
2
|
9
|
7
|
4
|
2
|
1
|
|
Cash from Investing |
14
|
49
|
10
|
-3
|
2
|
-86
|
|
Capex |
14
|
1
|
2
|
12
|
7
|
5
|
|
Cash from Financing |
-14
|
74
|
68
|
78
|
21
|
1
|
|
Stock Issued |
23
|
51
|
68
|
66
|
1
|
1
|
|
Debt (LT) Issued |
-37
|
0
|
0
|
12
|
20
|
0
|
|
Free Cash Flow |
-85
|
27
|
-75
|
-89
|
-111
|
-73
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
1.6
|
1.2
|
6.0
|
8.4
|
7.0
|
13.0
|
|
Financial Leverage D/E |
-
|
-
|
0.53
|
0.41
|
0.21
|
0.00
|
|
Return on Capital Avg |
-
|
-
|
-133.7%
|
-115.6%
|
-86.0%
|
-116.6%
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available